IL-7 is superior to IL-2 for ex vivo expansion of tumourspecific CD4 + T cells

37Citations
Citations of this article
58Readers
Mendeley users who have this article in their library.

Abstract

It is well established that tumours hinder both natural and vaccine-induced tumourspecific CD4+ T-cell responses. Adoptive T-cell therapy has the potential to circumvent functional tolerance and enhance anti-tumour protective responses. While protocols suitable for the expansion of cytotoxic CD8+ T cells are currently available, data on tumour-specific CD4+ T cells remain scarce.We report here that CD4+ T cells sensitized to tumour-associated Ag in vivo, proliferate in vitro in response to IL-7 without the need for exogenous Ag stimulation and accumulate several folds while preserving a memory-like phenotype. Both cell proliferation and survival accounts for the outgrowth of tumoursensitized T cells among other memory and naive lymphocytes following exposure to IL-7. Also IL-2, previously used to expand anti-tumour CTL, promotes tumour-specific CD4+ T-cell accumulation. However, IL-7 is superior to IL-2 at preserving lymphocyte viability, in vitro and in vivo, maintaining those properties, that are required by helper CD4+ T cells to confer therapeutic efficacy upon transplantation in tumour-bearing hosts. Together our data support a unique role for IL-7 in retrieving memory-like CD4+ T cells suitable for adoptive T-cell therapy. © 2010 Wiley-VCH Verlag GmbH & Co. KGaA.

Cite

CITATION STYLE

APA

Caserta, S., Alessi, P., Basso, V., & Mondino, A. (2010). IL-7 is superior to IL-2 for ex vivo expansion of tumourspecific CD4 + T cells. European Journal of Immunology, 40(2), 470–479. https://doi.org/10.1002/eji.200939801

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free